Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07159763 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Safety and Efficacy of CD388 for Prevention of Influenza
A Phase 3 study of Influenza, sponsored by Cidara Therapeutics.
- Active
- Registry status
- Phase 3
- Development phase
- 7,500
- Enrollment target
- 20
- Study locations
NCT07159763: Active Phase 3 study of Influenza, sponsored by Cidara Therapeutics.
NCT07159763 is a Phase 3 study of Influenza that is active but no longer recruiting, run by Cidara Therapeutics. The registered enrollment target is 7,500 participants, below the 36,756-participant average among 156 other Influenza trials with a reported enrollment target (80% lower). The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07159763, a Phase 3 study of Influenza, is active but no longer recruiting, sponsored by Cidara Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 7,500 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate how well CD388 works in preventing symptomatic laboratory-confirmed influenza infections, as compared to placebo, when given as a single dose via 3 subcutaneous (SQ) injections to adult and adolescent participants who are at higher risk of developing influenza complications, and to evaluate the safety and tolerability of CD388, as compared to placebo.
Primary Outcome
Percentage of participants experiencing protocol-defined ILI occurring after administration of CD388, with influenza infection confirmed by a reverse-transcriptase polymerase chain reaction positive (RT-PCR+) result based on a nasopharyngeal (NP) swab assayed at a central laboratory (first occurrence only), as compared to placebo.
Conditions Studied
Interventions
- COMBINATION_PRODUCT Placebo
- COMBINATION_PRODUCT CD388 Injection
Study Locations (20)
California
- Triallogix Medical Corporation - Fullerton
- National Institute of Clinical Research, Inc. - Garden Grove
- Eximia Research-CA, LLC - La Mesa
- Kinetic Clinical Research, LLC dba Long Beach Clinical Trials - Long Beach
- Seaside Medical Group - Oceanside
- Profound Research, LLC - Pasadena
- Paradigm Clinical Research - Redding
- Artemis Institute for Clinical Research - San Diego
- Acclaim Clinical Research - San Diego
- Diablo Clinical Research, Inc. - Walnut Creek
Arizona
- HOPE Research Institute - Glendale
- Desert Clinical Research, LLC / Avacare - Mesa
- Foothills Research Center / Avacare - Phoenix
- Fiel Family and Sports Medicine / Avacare - Tempe
- HOPE Research Institute - Tempe
- Arizona Clinical Trials - Tucson
- Del Sol Research Management, LLC - Tucson
Alabama
- Pinnacle Research Group, LLC - Anniston
- Cullman Clinical Trials - Cullman
Colorado
- Tekton Research, LLC - Denver
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7,500 participants |
| Start Date | 2025-09-25 |
| Est. Completion | 2027-01 |
| Phase | Phase 3 |
What the registry record for NCT07159763 still lists
NCT07159763 is an interventional study that assigns participants to a tested intervention. Its 7,500 participants enrollment target places it among the larger protocols in the corpus, below the 36,756-participant average among 156 other Influenza trials with a reported enrollment target (80% lower).
The record links to 1 condition, with Influenza appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07159763 names 20 study sites across 4 states, led by California, Arizona, Alabama.
Frequently Asked Questions
What is clinical trial NCT07159763 about?
NCT07159763 is a clinical study titled "A Study to Evaluate the Safety and Efficacy of CD388 for Prevention of Influenza". The purpose of this study is to evaluate how well CD388 works in preventing symptomatic laboratory-confirmed influenza infections, as compared to placebo, when given as a single dose via 3 subcutaneous (SQ) injections to adult and adolescent participants who are at higher risk of developing influenz...
What is the current status of trial NCT07159763?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 7,500 participants. The study started on 2025-09-25. Estimated completion is 2027-01.
What conditions does trial NCT07159763 study?
This clinical trial studies the following conditions: Influenza.
What interventions are being tested in trial NCT07159763?
The interventions under investigation include: Placebo (COMBINATION_PRODUCT), CD388 Injection (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT07159763?
This trial is sponsored by Cidara Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07159763 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Influenza
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07159763's enrollment target sits among peer trials
7,500 14th of 156 higher than 143 of 156 other Influenza trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Influenza trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Surveillance Study of Susceptibility to Baloxavir Marboxil in Pediatric Participants With Influenza and Transmission of Influenza to Household Contacts
RECRUITING · Phase 3
-
Immunogenicity & Safety of GSK's Influenza Vaccine 1557484A Given to Adults Aged ≥18 Years
COMPLETED · Phase 3
-
Study to Evaluate Immunogenicity and Safety of a High-Dose Influenza Vaccine in Adults 50 Through 64 Years of Age
COMPLETED · Phase 3
-
Study of Quadrivalent Influenza Vaccine Among Children
COMPLETED · Phase 3
-
Comparison of the Safety of Flublok® Versus Licensed IIV in Healthy, Medically Stable Adults ≥ 50 Years of Age
COMPLETED · Phase 3
-
Study to Assess Efficacy and Safety of Baloxavir Marboxil In Combination With Standard-of-Care Neuraminidase Inhibitor In Hospitalized Participants With Severe Influenza
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00439049 · 7,500 participants
Substance Abuse Pre-Treatment Screening Study
- NCT04809740 · 7,500 participants · NA
Evaluating the Implementation and Impact of Navigator-delivered ePRO System
- NCT05199701 · 7,500 participants · NA
Prospective Case Collection Study for New Mammography Technologies
- NCT06112418 · 7,500 participants · NA
A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI